Acute lymphoblastic leukemia (ALL) is the most common cancer in children with approximately 3,250 new cases occurring per year in the United States. About 20% of cases are refractory to current treatment protocols and there is a desperate need for targeted therapies that do not result in adverse side effects such as cognitive impairment.
The Interleukin-7 receptor-α (IL-7Rα) was identified as a major pathway driving T-cell derived ALL (T-ALL). Researchers at the National Cancer Institute (NCI) developed antibodies selectively targeting IL-7Rα. Two lead antibody candidates, designated 4A10 and 2B8, selectively bind IL-7Rα with nanomolar affinity. Each lead antibody mediates leukemic cell killing by antibody-dependent cellular cytotoxicity (ADCC) and causes a significant reduction in T-ALL cell burden when administered in a xenograft mouse model harboring patient derived leukemia. Tumor reduction occurred despite the absence of ADCC immune effector cells in the xenograft mouse model. Furthermore, a synergistic effect occurred when combining the IL-7Rα antibody with AMD3100, a commercially available CXCR4 antagonist approved as a therapeutic in humans. The combination treatment resulted in a significant improvement in clearance of T-ALL cell burden in a xenograft mouse model.
The National Cancer Institute (NCI) seeks licensing and/or co-development research collaborations for the further development of these IL-7Rα-selective antibodies as targeted therapies for a range of indications including oncology and autoimmune disorders. Examples include cell acute lymphoblastic leukemia (T-ALL), B-cell acute lymphoblastic leukemia (B-ALL), several autoimmune disorders (Type 1 diabetes and multiple sclerosis) and organ transplant rejection.
- Targeted therapy for various cancers including T-cell acute lymphoblastic leukemia (T-ALL) and B-cell acute lymphoblastic leukemia (B-ALL)
- Targeted therapy for several autoimmune disorders (Type 1 diabetes and multiple sclerosis), organ transplant rejection, Type 1 diabetes, and multiple sclerosis
- Selectively bind IL-7Rα with high (nanomolar) affinity
- Mediates cancer cell killing through antibody-dependent cellular cytotoxicity (ADCC)
- Targeted therapy with potential for fewer and less severe adverse events
- Well-established regulatory path
- Numerous approved products using same approach (e.g., Rituximab, and Cetuximab)
- U.S. Provisional: U.S. Provisional Patent Application Number 62/238,612, Filed 07 Oct 2015
- U.S. Patent Filed: U.S. Patent Application Number PCT/US2016/055957, Filed 07 Oct 2016